# Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Canonical URL: https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0
Ticker: LEGN
Company: Legend Biotech Corporation
Source: Legend Biotech Corporation
Published: 2026-07-28 12:00 EST
## Summary

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will...

## Article Body
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results.

During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.

Investors and other interested parties may access the live audio webcast via this weblink .

A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI ® , a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X , Instagram , and LinkedIn .

INVESTOR CONTACT: Caroline Paul Tel: (973) 650-5832 Caroline.Paul@legendbiotech.com

PRESS CONTACT: Kim Fox Tel: (848) 388-8445 media@legendbiotech.com
## Recent Company News
- 2026-07-28 12:00 EST — [Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0) — Source: Legend Biotech Corporation
- 2026-07-27 10:00 EST — [Legend Biotech Announces CEO Transition](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-ceo-transition-6f26346e) — Source: Legend Biotech Corporation
- 2026-06-18 01:21 EST — [Legend Biotech Corporation Announces Pricing of Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-c0ab1d0b) — Source: Legend Biotech Corporation
- 2026-06-17 20:29 EST — [Legend Biotech Corporation Announces Proposed Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-3615b70e) — Source: Legend Biotech Corporation
- 2026-06-15 12:00 EST — [Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma](https://biopharmsignal.com/news/LEGN/legend-biotech-establishes-clinical-proof-of-concept-for-lb2501-a-potential-firs-fb89efa6) — Source: Legend Biotech Corporation
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)